CASMED of Branford, Connecticut has received FDA clearance for the company’s FORE-SIGHT Absolute Tissue Oximeter to be used as a monitoring tool of regional oxygenation of skeletal musculature in children between 5 and 50 Kg. The device was previously approved for monitoring of blood oxygen saturation in the brain in critical care and intraoperative cases.
From the product page:
Accurate, reliable, absolute:
Unique 4 wavelength, LASER-SIGHT® Optical Technology and patented algorithm deliver accurate, reliable, absolute measurements.
Instantly evaluate a patient’s cerebral oxygen saturation status. Ideal for identifying compromised patients in a variety of clinical settings.
Non-invasive and continuous:
Optimal for use in perioperative settings for continuous, non-invasive measurement of cerebral oxygen saturation status.
Catastrophic event avoidance:
Observe and intervene to reverse desaturation events as they occur.
Enhanced response time:
Instantaneous feedback enables swift response times. Data is updated every 2 seconds.
Extensive clinical utility:
Delivers accurate measurements over a wide variety of perfusion conditions including low and zero perfusion states. Measurements are not affected by patient temperature.
Improved work flow:
Because it’s absolute, there is no need for a pre-induction baseline reading. Monitoring can begin at any time.
Press release: FORE-SIGHT Indicated for Monitoring of Skeletal Muscle Oxygenation…
Product page: FORE-SIGHT…